A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults

Tumor median progression-free survival (PFS) time

Including clinical and radiographic assessments defined as the time between the start date of cabozantinib in combination with nivolumab and the date of progression or death of any cause. The Kaplan-Meier method will be used to estimate median PFS.

Time frame: Every month until month 4, and every 3 months after month 4 up to 42 month or disease progression

Proportion of participants who achieve partial or complete response (Objective Response Rate (ORR))

Assessed by the investigator

Time frame: Every month until month 4, and every 3 months after month 4 up to 42 month or disease progression

Duration of response (DOR)

Defined as the interval from the date of first response (complete or partial) to treatment with cabozantinib in combination with nivolumab, to progressive disease or death

Time frame: Every month until month 4, and every 3 months after month 4 up to 42 month or disease progression

Proportion of participants who achieve complete response, partial response or stable disease (Disease Control Rate (DCR)).

Time frame: Every month until month 4, and every 3 months after month 4 up to 42 months or disease progression.

Time of response (TTR)

Defined as the time between the start date of cabozantinib in combination with nivolumab and date of first response (complete or partial).

Time frame: Every month until month 4, and every 3 months after month 4 up to 42 months or disease progression